Polymyositis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Argenx, Immunoforge Co. Ltd., Chester Oddis, Paean Biotechnology Inc., Kezar

The Polymyositis Market size was valued approximately USD 88 million in 2020 and the report offers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the 7MM.
DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Polymyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyositis Market Forecast [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Polymyositis Market Report:

*
The Polymyositis market size was valued approximately USD 88 million in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
According to DelveInsight's evaluation in 2022, the 7MM saw an estimated 184,204 diagnosed prevalent cases of Inflammatory Myositis. Projections suggest a notable upward trajectory in these cases, characterized by a substantial compound annual growth rate (CAGR) anticipated between 2023 and 2032.

*
Among the 90,064 diagnosed prevalent cases of Inflammatory Myositis, nearly 27,565 were attributed to Polymyositis in the US in 2022. Projections indicate a continued rise in these cases at a significant compound annual growth rate (CAGR) over the forecast period from 2023 to 2032.

*
In 2022, the EU4 and the UK collectively registered 34,459 diagnosed prevalent cases of Polymyositis. Within this group, Germany reported the highest number of diagnosed prevalent cases, totaling 11,185. Conversely, Spain had the lowest number of diagnosed prevalent cases among the EU4 and the UK, with a total of 3,504 cases.

*
According to Brent et al. (2023), Polymyositis is infrequently observed in pediatric patients, with the typical age range falling between 50 and 60 years. Additionally, there is an overall female-to-male ratio of 2 to 3:1.

*
Argenx is progressing with the clinical development of Efgartigimod, currently in Phase II/III trials, with anticipated launch during the forecast period. This launch is poised to notably expand the emerging market for Polymyositis.

*
Key Polymyositis Companies: Argenx, Immunoforge Co. Ltd., Chester Oddis, Paean Biotechnology Inc., Kezar Life Sciences, Inc., EMD Serono R&D, Japan Blood Products Organization, Tokyo Medical and Dental University, University of Pittsburgh, Immunoforge Co. Ltd., Bristol-Myers Squibb, NPO Petrovax, and others

*
Key Polymyositis Therapies: Efgartigimod, PF1801, tocilizumab, PN-101, KZR-616, M5049 high dose, GB-0998, Tacrolimus, Rituximab, Froniglutide, Abatacept subcutaneous, Longidaza Registered , and others

*
The Polymyositis epidemiology based on gender analyzed that Polymyositis affects females more as compared to males

*
The Polymyositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polymyositis pipeline products will significantly revolutionize the Polymyositis market dynamics.

Polymyositis Overview

Polymyositis is a rare inflammatory muscle disease characterized by muscle weakness and inflammation. It primarily affects the skeletal muscles, leading to symptoms such as muscle weakness, difficulty in swallowing, fatigue, and muscle pain. Polymyositis is considered an autoimmune disorder, where the body's immune system mistakenly attacks its own muscles, leading to inflammation and muscle damage.

Get a Free sample for the Polymyositis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/polymyositis-market [https://www.delveinsight.com/report-store/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Polymyositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Polymyositis Epidemiology Segmentation:

The Polymyositis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Polymyositis

*
Prevalent Cases of Polymyositis by severity

*
Gender-specific Prevalence of Polymyositis

*
Diagnosed Cases of Episodic and Chronic Polymyositis

Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Epidemiology Forecast [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Polymyositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polymyositis market or expected to get launched during the study period. The analysis covers Polymyositis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Polymyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Polymyositis Therapies and Key Companies

*
Argenx: Efgartigimod

*
PF1801: Immunoforge Co. Ltd.

*
tocilizumab: Chester Oddis

*
PN-101: Paean Biotechnology Inc.

*
KZR-616: Kezar Life Sciences, Inc.

*
M5049 high dose: EMD Serono R&D

*
GB-0998: Japan Blood Products Organization

*
Tacrolimus: Tokyo Medical and Dental University

*
Rituximab: University of Pittsburgh

*
Froniglutide: Immunoforge Co. Ltd.

*
Abatacept subcutaneous: Bristol-Myers Squibb

*
Longidaza Registered : NPO Petrovax

Discover more about therapies set to grab major Polymyositis market share @ Polymyositis Treatment Landscape [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Polymyositis Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Polymyositis Companies: Argenx, Immunoforge Co. Ltd., Chester Oddis, Paean Biotechnology Inc., Kezar Life Sciences, Inc., EMD Serono R&D, Japan Blood Products Organization, Tokyo Medical and Dental University, University of Pittsburgh, Immunoforge Co. Ltd., Bristol-Myers Squibb, NPO Petrovax, and others

*
Key Polymyositis Therapies: Efgartigimod, PF1801, tocilizumab, PN-101, KZR-616, M5049 high dose, GB-0998, Tacrolimus, Rituximab, Froniglutide, Abatacept subcutaneous, Longidaza Registered , and others

*
Polymyositis Therapeutic Assessment: Polymyositis current marketed and Polymyositis emerging therapies

*
Polymyositis Market Dynamics: Polymyositis market drivers and Polymyositis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Polymyositis Unmet Needs, KOL's views, Analyst's views, Polymyositis Market Access and Reimbursement

To know more about Polymyositis companies working in the treatment market, visit @ Polymyositis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Polymyositis Market Report Introduction

2. Executive Summary for Polymyositis

3. SWOT analysis of Polymyositis

4. Polymyositis Patient Share (%) Overview at a Glance

5. Polymyositis Market Overview at a Glance

6. Polymyositis Disease Background and Overview

7. Polymyositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Polymyositis

9. Polymyositis Current Treatment and Medical Practices

10. Polymyositis Unmet Needs

11. Polymyositis Emerging Therapies

12. Polymyositis Market Outlook

13. Country-Wise Polymyositis Market Analysis (2019-2032)

14. Polymyositis Market Access and Reimbursement of Therapies

15. Polymyositis Market Drivers

16. Polymyositis Market Barriers

17. Polymyositis Appendix

18. Polymyositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polymyositis-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-argenx-immunoforge-co-ltd-chester-oddis-paean-biotechnology-inc-kezar]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.